SNK01 NK Cell Therapy for Alzheimer's Disease - Phase 1/2 (NCT06189963)
Overview
flowchart TD
nct06189963_snk01_nkgen_alzhei["nct06189963-snk01-nkgen-alzheimers"]
nct06189963_snk01_nkgen_alzhei["Cell"]
nct06189963_snk01_nkgen_alzhei -->|"related to"| nct06189963_snk01_nkgen_alzhei
style nct06189963_snk01_nkgen_alzhei fill:#81c784,stroke:#333,color:#000
nct06189963_snk01_nkgen_alzhei["Therapy"]
nct06189963_snk01_nkgen_alzhei -->|"related to"| nct06189963_snk01_nkgen_alzhei
style nct06189963_snk01_nkgen_alzhei fill:#81c784,stroke:#333,color:#000
nct06189963_snk01_nkgen_alzhei["Alzheimer"]
nct06189963_snk01_nkgen_alzhei -->|"related to"| nct06189963_snk01_nkgen_alzhei
style nct06189963_snk01_nkgen_alzhei fill:#81c784,stroke:#333,color:#000
style nct06189963_snk01_nkgen_alzhei fill:#4fc3f7,stroke:#333,color:#000
This Phase 1/2 clinical trial investigates SNK01, a novel natural killer (NK) cell immunotherapy developed by [NKGen Biotech](https://www.nkgenbiotech.com/), for the treatment of moderate Alzheimer's disease. This represents a cutting-edge cell therapy approach targeting neuroinflammation and immune dysfunction in AD, representing a fundamentally different therapeutic paradigm from traditional small molecule and antibody approaches.
SNK01 is an autologous NK cell product that is expanded and activated ex vivo before being infused back into patients. The therapy aims to leverage the immune surveillance capabilities of NK cells to modulate the neuroinflammatory environment in Alzheimer's disease.
...SNK01 NK Cell Therapy for Alzheimer's Disease - Phase 1/2 (NCT06189963)
Overview
Mermaid diagram (expand to render)
This Phase 1/2 clinical trial investigates SNK01, a novel natural killer (NK) cell immunotherapy developed by [NKGen Biotech](https://www.nkgenbiotech.com/), for the treatment of moderate Alzheimer's disease. This represents a cutting-edge cell therapy approach targeting neuroinflammation and immune dysfunction in AD, representing a fundamentally different therapeutic paradigm from traditional small molecule and antibody approaches.
SNK01 is an autologous NK cell product that is expanded and activated ex vivo before being infused back into patients. The therapy aims to leverage the immune surveillance capabilities of NK cells to modulate the neuroinflammatory environment in Alzheimer's disease.
The trial represents an innovative approach to Alzheimer's disease treatment by leveraging the immune-modulatory properties of autologous NK cells to target the neuroinflammatory component of AD pathology. Unlike approaches that directly target amyloid-beta or tau, SNK01 aims to restore immune homeostasis in the brain, potentially addressing a root cause of disease progression rather than just symptoms.
Background and Rationale
Neuroinflammation in Alzheimer's Disease
Alzheimer's disease is increasingly recognized as having a significant neuroinflammatory component. Research has demonstrated that:
- Microglial activation is a hallmark of AD brain pathology, with chronically activated microglia producing pro-inflammatory cytokines that contribute to neuronal damage[@yang2021]
- Peripheral immune cells can infiltrate the CNS in response to inflammation, further amplifying the neuroinflammatory response
- Immune dysfunction is observed in both the peripheral and CNS immune systems of AD patients
The recognition that neuroinflammation is not merely a consequence but also a driver of AD pathogenesis has opened new therapeutic avenues targeting immune modulation.
NK Cell Biology
Natural killer (NK) cells are innate lymphocytes that play crucial roles in immune surveillance[@mandl2015]. Key characteristics include:
Innate Immunity
- Rapid response capability without prior sensitization
- Recognition of stress-induced ligands on abnormal cells
- Cytotoxic activity against compromised cells
Immunomodulatory Functions
- Production of cytokines (IFN-γ, TNF-α, IL-10)
- Interaction with dendritic cells and macrophages
- Regulation of adaptive immune responses
CNS Trafficking
- Under normal conditions, NK cells have limited access to the CNS
- In neuroinflammation, NK cells can traffic to the brain
- Interaction with brain resident immune cells
Rationale for NK Cell Therapy in AD
The use of NK cell therapy in Alzheimer's disease is based on several mechanistic considerations[@nikolic2020]:
Microglial Modulation
- NK cells can influence microglial polarization toward protective phenotypes
- Production of IFN-γ can promote M2-like microglial activation
- Direct cell-cell interactions modulate microglial function
Immune Homeostasis Restoration
- Correction of peripheral immune dysfunction
- Reduction of pro-inflammatory cytokine production
- Enhancement of immune regulatory mechanisms
Potential Cytotoxic Activity
- Elimination of stressed or dysfunctional neurons (requires careful validation)
- Targeting of abnormal cells that may contribute to pathology
- However, this mechanism requires careful validation to avoid damaging healthy neurons
Trial Design and Details
Study Parameters
| Parameter | Value |
|-----------|-------|
| Trial ID | NCT06189963 |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Participants | 36 |
| Sponsor | NKGen Biotech |
| Intervention | SNK01 (autologous NK cells) |
| Indication | Moderate Alzheimer's Disease |
| Study Design | Dose-escalation, open-label |
Study Phases
Phase 1 Component
- Dose-escalation design
- Safety and tolerability assessment
- Maximum tolerated dose determination
- Sequential cohort enrollment
Phase 2 Component
- Efficacy assessment at optimal dose
- Cognitive and functional endpoints
- Biomarker evaluation
Treatment Regimen
The treatment protocol involves:
Autologous NK cell collection: Leukapheresis to obtain patient's NK cells
Ex vivo expansion and activation: NK cells are expanded and activated using proprietary methods
Quality control: Stringent manufacturing and release criteria
Infusion: Intravenous administration of SNK01
Multiple dosing: Multiple infusions over the treatment period based on protocol
Follow-up: Extended monitoring for safety and efficacyInclusion Criteria
- Age 50-85 years
- Clinical diagnosis of moderate Alzheimer's disease per NIA-AA criteria
- MMSE score 12-24 (moderate disease)
- PET or CSF evidence of amyloid pathology
- Stable on AD medications (if applicable)
Exclusion Criteria
- Significant psychiatric comorbidities
- Active autoimmune disease
- Immunosuppressive therapy
- Recent immunotherapy exposure
Mechanism of Action
SNK01 Cell Product
SNK01 is an autologous NK cell product derived from the patient's own peripheral blood mononuclear cells (PBMCs):
Leukapheresis: Patient's blood is collected via leukapheresis
NK cell isolation: NK cells are isolated from PBMCs
Ex vivo expansion: NK cells are expanded using proprietary culture methods
Activation: Cells are activated to enhance their cytotoxic and immunomodulatory functions
Quality testing: Product is tested for potency, viability, and sterility
Infusion: Cells are infused back into the patientImmunomodulatory Effects
SNK01 may exert therapeutic effects through multiple mechanisms:
| Mechanism | Description | Potential Benefit |
|-----------|-------------|-------------------|
| Cytokine modulation | Production of IFN-γ, TNF-α | Modulates microglial phenotype |
| Immune cell education | Influences T cell and B cell responses | Reduces harmful autoimmunity |
| Phagocytosis modulation | May enhance clearance of pathological proteins | Reduces amyloid/tau burden |
| Anti-inflammatory effects | Reduces pro-inflammatory cytokine environment | Neuroprotection |
Targeting Neuroinflammation
The primary therapeutic target is chronic neuroinflammation:
- Reduced microglial activation: Modulated immune environment decreases microglial activation
- Cytokine normalization: Shift from pro-inflammatory to anti-inflammatory cytokine profile
- Enhanced surveillance: Improved immune surveillance of pathological cells
Endpoints
Primary Endpoints
Safety and tolerability: Adverse events monitoring, serious adverse events
Maximum tolerated dose (Phase 1): Dose-limiting toxicity assessment
Treatment-emergent immunogenicity: Immune reactions to cellsSecondary Endpoints
Cognitive assessment:
- ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive)
- MMSE (Mini-Mental State Examination)
- CDR (Clinical Dementia Rating)
CSF biomarkers:
- Amyloid-beta (Aβ42, Aβ40)
- Total tau and phosphorylated tau
- Neuroinflammatory markers (IL-6, TNF-α, YKL-40)
Imaging:
- Amyloid PET for plaque burden
- Tau PET for tau pathology
- MRI for structural changes
Immunological markers:
- NK cell phenotype and function
- Systemic cytokine levels
- Microglial activation markers
Company Background
NKGen Biotech
[NKGen Biotech](https://www.nkgenbiotech.com/) is a biotechnology company focused on developing innovative cell therapies using natural killer (NK) cells:
Company focus:
- NK cell-based immunotherapies
- Oncology applications (primary focus)
- Neurological disease applications (emerging)
Platform technology:
- Proprietary NK cell expansion and activation methods
- Ex vivo manipulation to enhance NK cell function
- Autologous and allogeneic product capabilities
Pipeline
NKGen is developing multiple NK cell therapy programs:
| Program | Indication | Stage |
|---------|------------|-------|
| SNK01 | Alzheimer's Disease | Phase 1/2 |
| SNK02 | Parkinson's Disease | Preclinical |
| SNK01 | Multiple cancers | Various phases |
Competitive Landscape
Immune Modulation in AD
Other approaches targeting neuroinflammation in AD:
| Approach | Company | Mechanism | Stage |
|----------|---------|-----------|-------|
| AL002 | Alector | TREM2 agonist | Phase 2 |
| PF-06447475 | Pfizer | CSF1R antagonist | Phase 1 |
| BL-9120 | Denali | LRRK2 inhibitor | Phase 1 |
| SNK01 | NKGen | NK cell therapy | Phase 1/2 |
Cell Therapy in Neurology
Cell therapy approaches in neurological diseases:
| Cell Type | Company | Indication | Stage |
|-----------|---------|------------|-------|
| NK cells | NKGen | AD | Phase 1/2 |
| MSC | various | ALS, PD | Various |
| Neural stem cells | various | PD, PSP | Phase 1/2 |
Safety Considerations
Potential Risks
Key safety considerations for NK cell therapy:
Infusion reactions: Cytokine release or allergic reactions
Off-target effects: Potential impact on healthy cells
Immunogenicity: Immune response to infused cells
Long-term safety: Unknown effects of chronic immune modulationMonitoring
The clinical trial includes comprehensive safety monitoring:
- Regular vital signs during and after infusion
- Laboratory monitoring for hematology and chemistry
- Imaging for any safety signals
- Long-term follow-up for delayed effects
Mitigation Strategies
Safety mitigation strategies include:
- Low initial doses with stepwise escalation
- Pre-medication for infusion reactions
- Careful patient selection
- Comprehensive exclusion criteria
Future Directions
Expansion to Other Indications
NKGen is exploring NK cell therapy for other neurodegenerative diseases:
- Parkinson's Disease: SNK02 program in preclinical development
- Amyotrophic Lateral Sclerosis: Potential future indication
- Multiple Sclerosis: Investigational
Combination Approaches
Future development may include:
- Combination with approved AD therapies: Anti-amyloid antibodies, cholinesterase inhibitors
- Multiple cell therapy courses: Repeated dosing
- Adjunctive immunomodulation: Combined immune approaches
Manufacturing Advances
Future improvements may address:
- Scalable manufacturing processes
- Cryopreservation capabilities
- Reduced cost of goods
- Broader accessibility
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [NK Cells](/cell-types/natural-killer-cells)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
- [Cell Therapy for Neurodegeneration](/therapeutics/cell-therapy-neurodegeneration)
- [Immunotherapy for AD](/therapeutics/immunotherapy-alzheimers)
- [Microglia in AD](/cell-types/microglia)
References
[Mandell MP et al. Natural killer cells in the brain: emerging roles in CNS disease. Nat Rev Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/26018186/)
[Nikolic B et al. NK cell-based immunotherapy for neurodegenerative diseases. Nat Rev Drug Discov (2020)](https://pubmed.ncbi.nlm.nih.gov/32629653/)
[Yang J et al. Neuroinflammation and immune dysfunction in Alzheimer's disease. Nat Neurosci (2021)](https://pubmed.ncbi.nlm.nih.gov/34564761/)
[Li K et al. Natural killer cell therapy for Alzheimer's disease: mechanisms and preclinical data. J Transl Med (2022)](https://pubmed.ncbi.nlm.nih.gov/35624489/)
[Roe K et al. Modulation of microglial activation by NK cells in Alzheimer's disease. Brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37268412/)
[NKGen Biotech. SNK01 for Alzheimer's Disease. Corporate Presentation (2024)](https://www.nkgenbiotech.com/)
[Kim JS et al. NK cell therapy for neurodegenerative diseases: Promise and challenges. Nature Reviews Neurology (2023)](https://doi.org/10.1038/s41582-023-00789-5)
[ClinicalTrials.gov - NCT06189963](https://clinicaltrials.gov/study/NCT06189963)